{"entity":{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","aka":[],"tldr":"Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.","summary":"FirstLook Lung (launched 2023) analyses cfDNA fragmentation patterns to identify who should proceed to low-dose CT. The L301 FIRSTLUNG cluster-randomised trial (NCT06145750) was presented as a late-breaker at ATS 2026; AACR 2026 showed whole-genome cfDNA advances in detection and monitoring. Johns Hopkins spin-out.","asOf":"2026-09-04","links":[{"label":"ATS 2026","url":"https://www.biospace.com/press-releases/delfi-diagnostics-to-present-first-clinical-utility-data-for-blood-based-lung-cancer-screening-at-ats-2026-international-conference"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["early-detection"],"technologies":["fragmentomics","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Baltimore, MD","country":"US","companyType":"diagnostics","website":"https://delfidiagnostics.com","investors":["illumina-ventures"],"funding":[]},"route":"/companies/delfi-diagnostics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"company":[{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/"}],"bottleneck":[{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"idea":[{"id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/"},{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}